Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biogen (BIIB) and ACADIA Pharmaceuticals (ACAD).
Biogen (BIIB)
In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Biogen, with a price target of $276.00. The company’s shares closed last Monday at $269.89.
According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 13.0% and a 55.5% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Proteostasis Therapeutics, and Intra-Cellular Therapies.
Biogen has an analyst consensus of Hold, with a price target consensus of $306.39, which is a 14.3% upside from current levels. In a report issued on June 22, Barclays also downgraded the stock to Hold with a $280.00 price target.
See today’s analyst top recommended stocks >>
ACADIA Pharmaceuticals (ACAD)
In a report released today, Gregory Renza from RBC Capital maintained a Buy rating on ACADIA Pharmaceuticals, with a price target of $58.00. The company’s shares closed last Monday at $53.02, close to its 52-week high of $53.75.
According to TipRanks.com, Renza is a 5-star analyst with an average return of 38.3% and a 55.6% success rate. Renza covers the Healthcare sector, focusing on stocks such as Inovio Pharmaceuticals, Iterum Therapeutics, and Aptose Biosciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for ACADIA Pharmaceuticals with a $59.33 average price target, a 12.4% upside from current levels. In a report issued on June 23, Jefferies also maintained a Buy rating on the stock with a $60.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ACAD:
